Clinical trial: a novel high-dose 1 g mesalamine suppository (Salofalk) once daily is as efficacious as a 500-mg suppository thrice daily in active ulcerative proctitis. [electronic resource]
Producer: 20110211Description: 1947-56 p. digitalISSN:- 1536-4844
- Adolescent
- Adult
- Aged
- Anti-Inflammatory Agents, Non-Steroidal -- administration & dosage
- Colitis, Ulcerative -- drug therapy
- Drug Administration Schedule
- Female
- Humans
- Male
- Mesalamine -- administration & dosage
- Middle Aged
- Patient Preference
- Proctitis -- drug therapy
- Remission Induction
- Single-Blind Method
- Suppositories
- Young Adult
No physical items for this record
Publication Type: Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.